Noninvasive near-infrared live imaging of human adult mesenchymal stem cells transplanted in a rodent model of Parkinson's disease.

International Journal of Nanomedicine
P BossolascoM-T Armentero

Abstract

We have previously shown that human mesenchymal stem cells (hMSCs) can reduce toxin-induced neurodegeneration in a well characterized rodent model of Parkinson's disease. However, the precise mechanisms, optimal cell concentration required for neuroprotection, and detailed cell tracking need to be defined. We exploited a near-infrared imaging platform to perform noninvasive tracing following transplantation of tagged hMSCs in live parkinsonian rats. hMSCs were labeled both with a membrane intercalating dye, emitting in the near- infrared 815 nm spectrum, and the nuclear counterstain, Hoechst 33258. Effects of near-infrared dye on cell metabolism and proliferation were extensively evaluated in vitro. Tagged hMSCs were then administered to parkinsonian rats bearing a 6-hydroxydopamine-induced lesion of the nigrostriatal pathway, via two alternative routes, ie, intrastriatal or intranasal, and the cells were tracked in vivo and ex vivo using near-infrared technology. In vitro, NIR815 staining was stable in long-term hMSC cultures and did not interfere with cell metabolism or proliferation. A significant near-infrared signal was detectable in vivo, confined around the injection site for up to 14 days after intrastriatal transplanta...Continue Reading

References

May 5, 2005·Experimental Neurology·P BossolascoE Polli
Jun 17, 2006·Current Opinion in Pharmacology·Mauro KramperaFrancesco Annunziato
Dec 14, 2007·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Gary D Luker, Kathryn E Luker
Jul 4, 2008·Parkinsonism & Related Disorders·Fabio BlandiniEmilia Martignoni
Aug 7, 2008·Cell Stem Cell·Lino FerreiraRobert Langer
Jul 9, 2009·Chemical Communications : Chem Comm·Scott A HilderbrandRalph Weissleder
Nov 3, 2009·Current Opinion in Chemical Biology·Scott A Hilderbrand, Ralph Weissleder
Nov 12, 2009·Future Oncology·Nobuyuki KosakaHisataka Kobayashi
Dec 8, 2009·Conference Proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society·Summer L Gibbs-StraussJohn V Frangioni
Mar 30, 2010·Analytical and Bioanalytical Chemistry·Ravindran Girija AswathyD Sakthi Kumar
Sep 28, 2010·Trends in Molecular Medicine·Xiaoxiao HeZhen Cheng
Oct 5, 2010·Progress in Brain Research·Patrik BrundinMalin Parmar
Oct 14, 2010·Journal of Molecular Neuroscience : MN·Leah R HansonRobert A Marr
Jan 25, 2011·The Mount Sinai Journal of Medicine, New York·Dustin R WakemanJeffrey H Kordower

❮ Previous
Next ❯

Citations

Nov 9, 2012·Pharmaceutical Research·Colin D ChapmanChristian Benedict
Mar 7, 2013·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Marco BisagliaLuigi Bubacco
Mar 26, 2021·Stem Cell Research & Therapy·Yu-Ting ZhangChun-Feng Liu

❮ Previous
Next ❯

Methods Mentioned

BETA
sedation
flow cytometry
transfection

Software Mentioned

Diva
Odyssey
Neurolucida

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.